Background: Currently, most chronic kidney disease (CKD) classifications identify patients at different stages of CKD but do not identify risk of progression or adverse outcome. This analysis aims to describe associations between baseline characteristics and the evolution of estimated glomerular filtration rate (eGFR) and identify threshold values for clinical parameters that maximally discriminate progression to renal replacement therapy (RRT) in a referred cohort of patients with CKD stages 3À5. Design and methods: A longitudinal mixed-effect model was used to determine annualized estimated change in eGFR and classification tree analysis to identify threshold values that maximally discriminate progression to RRT. Results: A total of 1316 patients were available for analysis with median follow-up of 33 months (interquartile range 20-60). Mixed model analysis suggested that the underlying diagnoses of
Introduction
While the current five-stage National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) classification 1 identifies patients at different stages of chronic kidney disease (CKD), it does not identify risk of progression or adverse outcome and makes no allowance for underlying cause of kidney disease.
There is considerable intra-disease variability in the rate of change of estimated glomerular filtration rate (eGFR) over time, and also between individuals with CKD due to the same disease, which likely represents the complex multi-factorial epidemiology of kidney disease.
There is no consensus definition of what constitutes progressive kidney disease. Current clinical guideline definitions of progression vary from decline in eGFR >5 ml/min/year or >10 ml/min within 5 years, doubling of serum creatinine, progression to end-stage renal disease (ESRD)/initiation of renal replacement therapy (RRT) or increasing proteinuria/albuminuria, to decline in CKD stage accompanied by 525% decline in baseline eGFR. [2] [3] [4] [5] It has been suggested that there is considerable variability in the evolution of kidney disease, demonstrated by a significant proportion of patients with CKD exhibiting non-progressive kidney disease in both large clinical trials and also observational cohorts. [6] [7] [8] [9] [10] Modification of the current clinical guidelines pertaining to the classification of CKD has been recommended by Kidney Disease Improving Global Outcomes (KDIGO) 11 to: (i) include classification by primary cause of kidney disease, (ii) include stages of albuminuria; Albumin Creatinine Ratio <30, 30-300 and >300 mg/g and (iii) subdivide stage 3 CKD into CKD stage 3a (eGFR 45-59 ml/ min) and 3b (30-44 ml/min).
There are still many unanswered questions with regard to the epidemiology of CKD as well as in our current understanding of the progression of CKD in patients managed in both primary and secondary care. In particular, knowledge of the evolution of eGFR and epidemiology of kidney disease in patients referred to renal services is limited.
Predicting the future trajectory of patients in the earlier stages of CKD will be vital to nephrologists and clinicians to help direct appropriate treatments targeting cardiovascular risk reduction and amelioration of progressive CKD as well as timely preparation for RRT.
The aim of this analysis was to describe the rate of change of eGFR by baseline CKD stage and primary renal disease and quantify associations between baseline characteristics and the evolution of eGFR in a large referred cohort of patients with CKD stages 3-5 (not on dialysis). In this referred cohort, we also aimed to identify thresholds with maximum sensitivity and specificity values using a receiver operating characteristic approach 12 and classification tree analysis to assess clinical variables that maximally discriminate progression to RRT.
Methods
The Chronic Renal Insufficiency Standards Implementation Study (CRISIS) is a prospective epidemiological investigation of the evolution of kidney disease and its associated co-morbidities in a referred population with CKD stages 3-5 receiving standard nephrological care in secondary care at Salford Royal Hospital NHS Foundation Trust, UK, the patients having been referred from a community population of 1.55 million.
Since 2002 a random sample of all patients with eGFR <60 and >10 ml/min [four-variable Modification of Diet in Renal Disease (MDRD) 13 ] referred to Salford Royal Hospital renal services have been approached to take part in the study at their initial clinic visit. Recruitment was undertaken in the out-patient department, at which time written consent was obtained and eligibility determined. Patients with previous evidence of RRT (dialysis or renal transplantation) were excluded from the study. At enrolment into the study and at annual follow-up, demographic, clinical and laboratory data were obtained from the electronic patient record (EPR), a continuously updated electronic health care system, as well as patient interview and detailed clinical examination. Variables available for analysis included:
Demographic data: age, gender, ethnicity, blood pressure, primary renal disease, prescribing data (by medication class) and self-reported smoking status. Renin angiotensin blockade (RAB) was defined as treatment with angiotensin converting enzyme inhibitors and/or angiotensin receptor blockers. Laboratory data: urea, creatinine, potassium, sodium, haemoglobin, calcium, phosphate, parathyroid hormone (PTH), albumin, C-reactive protein and cholesterol. Proteinuria was based on 24 h urinary protein collections and more recently urinary protein creatinine ratio. Co-morbidity data: angina, myocardial infarction, coronary angioplasty or stenting, coronary artery bypass graft, cardiac arrest, peripheral vascular disease, stroke or transient ischaemic attack.
All serum creatinine measurements were performed using a blank rated and compensated Jaffe reaction using a Roche Modular analyser. The method was calibrated in the laboratory as well as internal quality control, and the laboratory participates in the UK National External Quality Assessment Scheme. Creatinine measurements used to calculate eGFR were aligned to the Isotope Dilution Mass Spectrometry method. eGFR was calculated using a validated GFR estimate, the CKD Epidemiology Collaboration (CKD-EPI) equation 
Statistics
Normally distributed variables are presented as mean AE SD, or median and interquartile range (IQR) for skewed data and number with percentage for categorical variables. Covariates were compared across baseline eGFR by ANOVA for normal distributed variables, Kruskal-Wallis test for skewed continuous variables and chi-squared test for categorical variables. Mixed models, incorporating all GFR values from baseline onwards, were used to calculate rates of change of GFR. Thresholds of maximal combined sensitivity and specificity for RRT were determined. With this approach applied to a notional threshold for a continuous variable, sensitivity was the proportion of individuals destined to receive RRT classed as 'abnormal' by the notional threshold, while specificity was the proportion without RRT classified as 'normal'; an added proviso was a P-value, using logistic regression, for association with RRT. eGFR thresholds were examined between 9 and 57 in 1 ml/min/1.73 m 2 increments. For other continuous variables, the following ranges (increments) were examined: age, 30-85 (1 year); diastolic blood pressure (DBP), 50-100 (1 mmHg); proteinuria, 0.1-10 (0.1 g/day); body mass index, (1 kg/m 2 ); haemoglobin, 9.0-16.0 (0.1 g/dl); calcium, 2.00-2.60 (0.01 mmol/l); phosphate, 0.70-1.90 (0.01 mmol/l); PTH, 10-300 (1 pg/ml); albumin, 2.50-4.70 (0.01 g/dl); sodium 130-145 (1 mmol/l) and potassium, 3.50-6.00 (0.01 mmol/l). For classification tree analysis, the threshold exhibiting the highest sensitivity and specificity was used to subdivide the population into two subgroups, and an otherwise identical procedure to that described in the previous population was employed in each subgroup. Four iterations were performed and, ultimately, the terminal nodes were used to construct a classification system. Logistic regression was then employed to assess the performance of this classification system. P < 0.05 was considered statistically significant. Statistical analysis was performed using SPSS version 15.0 (SPSS Inc., www.spss.com) and SAS version 9.1 (SAS Institute, Cary, NC, USA).
Results
Records for 1316 patients enrolled into CRISIS between 1 October 2002 and 31 October 2009 were available for analysis (all patients enrolled who had 12 months or more follow-up, or RRT or death prior to this). Median follow-up time was 33 months (IQR 20-60). Baseline characteristics of the cohort are shown in Table 1 . Mean age at inception into the CRISIS cohort was 65.2 (AE13.9) years, mean eGFR was 29.0 (AE12.9), with a slight preponderance of men (63%). At baseline, cardiovascular disease (CVD) was prevalent in 51%, 60% were receiving RAB and a similar proportion received statin therapy; erythropoiesis stimulating agents (ESAs) were prescribed in 13%. DN was the aetiology in 17.3%, GN accounted for 19.0%, vascular causes [ARVD/hypertensive nephrosclerosis (HTN)] 22.3%, PN 7.7%, autosomal dominant polycystic kidney disease (ADPKD) 6.2% and 27.4% other or unknown causes.
The median annual rate of change in eGFR for the whole cohort was À1.18 ml/min/year (IQR: À3.58, 0.16 ml/min/year). Patients with stage 3a CKD at inception into the cohort were associated with more rapid median rates of decline in renal function at À2.06 ml/min/year compared with À1.24, À1.15 and À0.93 ml/min/year in those with CKD stages 3b, 4 and 5, respectively. Faster median rates of change in eGFR were seen in those patients with the underlying renal diagnosis of ADPKD (À4.36 ml/min/year), and to a lesser extent, DN (À1.69 ml/min/year). Table 2 includes the results of the multi-level mixed-effect model (repeated measures analysis) investigating the associations of the slope of eGFR over time with parameter estimates representing the absolute change of eGFR. Estimated average decline in eGFR was between 0.8 and 1.6 ml/min/year slower in those patients with eGFR <45 ml/min compared to those with eGFR 545 ml/min at baseline. Older age was similarly associated with slower average rates of decline in eGFR. Patients aged 62-73 and 573 years at inception to the cohort had, on average, 0.7 and 0.4 ml/min/year less rapid rates of decline in eGFR, respectively, compared with those 461 years of age. Proteinuria >0.9 g/day was associated with a more rapid rate of decline in eGFR $0.8 ml/min/year faster compared to those patients with 40.2 g/day.
The underlying diagnoses of ADPKD and DN exhibited on average a 2.7 and 0.7 ml/min/year faster rate of decline in eGFR, respectively, compared to those patients with GN. Higher DBP was associated with increased rates of progression between 0.4 and 0.6 ml/min/year faster than individuals with DBP 470 mmHg.
Use of RAB and active smokers were also associated with on average a 0.9-ml/min/year faster rate of decline in eGFR compared to those not prescribed RAB and non-smokers, respectively. Similarly, higher cholesterol was associated with more rapidly progressive CKD, with the middle tertile, 4.0-4.7 mmol/l, associated with a steeper decline in eGFR $0.6 ml/min/year faster compared to those with cholesterol levels 43.9 mmol/l. Other variables associated with more progressive CKD included higher serum PTH and potassium levels. Figure 1 shows sensitivity and specificity values for predicting RRT at different eGFR thresholds. A eGFR threshold value of 24 ml/min exhibited the highest maximum combined value of Sn/Sp for predicting RRT (Max Sn + Sp, Sn 0.82/Sp 0.69). The classification tree analysis (Figure 2) shows sequential subgroup threshold values with maximum sensitivity and specificity for predicting RRT. Among participants in the CRISIS cohort, eGFR 424 ml/min was the first ranked discriminator and was the first item chosen in the classification tree and formed the basis of the first two subgroups chosen; eGFR 424/>24 ml/ min. In those patients with eGFR >24 ml/min at baseline, DBP >79 mmHg was the best discriminator for progression to ESRD with DBP >73 mmHg selected for the subgroup with eGFR 424 ml/min. eGFR also appeared in the third round in two branches of the classification tree; eGFR > 24 ml/min/DBP > 79/ eGFR 4 31 and eGFR 4 24/DBP > 73/eGFR 4 18. Other classic risk factors including cholesterol and basal metabolic index (BMI) were first appeared in the third and fourth rounds, respectively. Table 3 shows RRT odds ratios for the terminal nodes of the classification tree ( Figure 2 ). The classification system appears to discriminate RRT risk satisfactorily (C-statistic 0.83).
Discussion
The results of the analysis of our cohort demonstrate the considerable variability in the evolution of eGFR and the prognostic importance of primary renal disease on the progression of CKD. In this large population with CKD stages 3-5, we describe clinical parameters associated with more rapid progression of kidney function. In addition, in the classification tree analysis we have identified threshold values for clinical variables that maximally discriminate progression to RRT in our referred cohort.
Routine reporting of eGFR has raised awareness of CKD. However, better information on the evolution of CKD is needed to further stratify and identify those patients at increased risk of progression to target management plans that can be appropriately incorporated into the routine care of individuals with kidney disease aimed at improving patient outcomes.
Some of the previous historical descriptions of the outcome of CKD suggest an unremitting, relentless progression through the stages of CKD to ESRD. This hypothesis has been challenged more recently, in particular by studies of patients with moderate to advanced kidney disease. [7] [8] [9] 15 Furthermore, our analysis has demonstrated an important separation in the evolution of eGFR over time based on the nature of the underlying primary renal disease. Those patients with ADPKD had significantly faster rates of decline in renal function, as to a lesser extent did DN patients, than those with GN, vascular causes, PN or other/unknown causes. In addition, results from the mixed model suggest that patients with eGFR 545 per ml/min had faster rates of decline in renal function than those with more advanced CKD, which seems somewhat counter-intuitive. However, the likely explanation is that patients with eGFR 545 were a younger subgroup of patients exhibiting more significantly progressive disease, and possibly that these individuals had been referred more recently to renal services with the consequence of less time for medical interventions to reduce the rate of progression of eGFR. These findings highlight the prognostic importance of primary renal disease on the progression of CKD in this referred cohort.
There is currently a paucity of information in the literature detailing the evolution of eGFR based on primary renal disease in large referred cohorts under specialist renal care. As with our study, the MDRD study reported that patients with ADPKD had more rapid rates of decline of eGFR compared to the overall cohort. based on primary renal disease with IgA nephropathy (eGFR slope À1.8 ml/min/year) and Focal Segmental Glomerular Sclerosis (À1.74 ml/min/ year) having more rapid rates of decline in kidney function, although both these aetiologies were associated with higher levels of proteinuria than the rest of this out-patient cohort. 16 More recently, significant differences in rates of change of eGFR based on primary renal disease have also been described by the Renal Registry (UK). 17 As mentioned earlier there is a need to improve the risk assessment of patients referred to renal services to identify those at greatest risk of progressive CKD. Variables associated with progression of CKD included: higher baseline eGFR, proteinuria (>0.9 g/day), younger age, underlying diagnoses of ADPKD and DN, higher DBP, smoking, higher serum cholesterol, PTH and potassium.
Levin et al. have also been able to characterize the patients at greatest risk of renal functional decline (>5 ml/min/year fall in eGFR) in a large referred CKD stage 4 cohort. Their findings were very similar to our own with younger age, higher eGFR, blood pressure, phosphate and PTH, and lower haemoglobin, serum calcium and albumin all being associated with rapid deterioration, however, the association of primary renal disease with change in eGFR was not examined in this study. 9 Smoking was associated with more rapid progression in our cohort, and this relationship has been shown in several other studies. [18] [19] [20] Although the initial analysis of the Study of Heart and Renal Protection trial showed benefit in reducing major cardiovascular events with lipid lowering, there was no evidence to suggest any effect of this on CKD progression. 21 Interestingly in our cohort, higher levels of cholesterol were associated with increased rates of progression in concordance with growing evidence from animal models. In addition, certain post hoc analyses of cardiovascular intervention studies suggest lipid lowering may retard progression of CKD. However, because of the observational nature of CRISIS we were unable to shed further light on this issue, but we acknowledge that this is a hypothetical link that requires further study.
Previous researchers have proposed development of risk scores that use readily available clinical parameters to aid clinicians in identifying patients at highest risk of progression to ESRD so that these patients can benefit from interventions to reduce CKD progression and also allow timely preparation for RRT. [22] [23] [24] [25] [26] [27] [28] [29] In a study of 9782 patients with CKD stages 2-4 from the Kaiser Permanente Northwest population, Johnson et al. developed a risk score that used six clinical variables (age, sex, diabetes, eGFR, anaemia and hypertension), which accurately predicted those patients at highest risk of progression to ESRD.
In the regression tree analysis, we have attempted to identify threshold values for easily obtainable Thresholds of maximal combined sensitivity and specificity for RRT were determined. With this approach applied to a notional threshold for a continuous variable, sensitivity was the proportion of individuals destined to receive RRT classed as 'abnormal' by the notional threshold, while specificity was the proportion without RRT classified as 'normal'; an added proviso was a P-value, using logistic regression, for association with RRT. eGFR thresholds were examined between 9 and 57 in 1 ml/min/1.73 m 2 increments. For other continuous variables, the following ranges (increments) were examined: age, 30-85 (1 year); DBP, 50-100 (1 mmHg); proteinuria, 0.1-10 (0.1 g/day); body mass index, 18-40 (1 kg/m 2 ); haemoglobin, 9.0-16.0 (0.1 g/dl); calcium, 2.00-2.60 (0.01 mmol/l); phosphate, 0.70-1.90 (0.01 mmol/l); PTH, 10-300 (1 pg/ml); albumin, 2.50-4.70 (0.01 g/dl); sodium 130-145 (1 mmol/l) and potassium, 3.50-6.00 (0.01 mmol/l). For classification tree analysis, the threshold exhibiting the highest sensitivity and specificity was used to subdivide the population into two subgroups, and an otherwise identical procedure to that described in the previous population was employed in each subgroup. Four iterations were performed and, ultimately, the terminal nodes were used to construct a classification system. clinical parameters that maximally discriminate progression to ESRD. This approach allows thresholds to be compared within and between variables thereby allowing us to identify the highest risk groups based on a few characteristics rather than clinical hunches. Because of its maximum combined sensitivity and specificity for predicting ESRD, eGFR 424 ml/min was the first item chosen, DBP appeared in the second round, eGFR appeared again in the third round together with cholesterol and systolic blood pressure (SBP), with BMI and DBP in the fourth round. The classification tree analysis suggests that by using a few clinical and biochemical variables it is possible to identify a group of patients at lower risk of progression who could be less intensively followed up or be managed in primary care, and a high risk cohort who should have individualized and directed treatment plans aimed at reducing the risk of progression and facilitating earlier planning for RRT.
Clinical validation of our own findings from CRISIS in other similar prospective studies of referred CKD may help improve the accuracy of these risk scores. This is particularly important as the primary reason for referral of many patients to nephrology services is because of reduced eGFR alone. Development of these predictive scores may also help clinicians identify a significant proportion of patients with non-progressive CKD who require different management plans (e.g. referral back to primary care for long-term management).
Our study has limitations, particularly relating to the observational nature of CRISIS. The timing of interventions (e.g. RAB treatment) has not been taken into account. We were reliant on the accuracy of clinician assessment of primary renal disease diagnosis in some cases-for example, only a minority of patients with DN had undergone diagnostic renal biopsy, and the diagnosis was made primarily on clinical grounds (diabetes with evidence of retinopathy and/or proteinuria). Finally, the CRISIS cohort consists of patients referred to renal services, hence, comparison of our findings to non-referred cohorts remains to be tested. The results of our study are, therefore, only generalizable to referred patients with more advanced CKD, managed under renal services. However, we feel that patients within this cohort are representative of those currently receiving standard nephrology care in the UK.
In summary, the results from this analysis of the CRISIS cohort emphasize the considerable variability in progression of CKD in a referred cohort and the importance of primary renal disease on the rate of evolution of eGFR over time. In line with the recently updated KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, 11 our data endorses the importance of inclusion of primary renal disease as well as quantification of level of proteinuria to predict the future clinical prognosis of patients with CKD.
We have highlighted risk factors for progressive renal disease and defined threshold values that maximally discriminate progression to ESRD. This analytical approach requires further validation and investigation in other similar populations, but the approach may be of benefit in developing more helpful CKD clinical guidelines in the future which would be of great clinical utility to both nephrologists and patients alike.
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